Betamethasone + Florfenicol + Terbinafine

Verify with FDA CVM →

2,221 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
2,221
Total Reports
38
Deaths Reported
170.0%
Death Rate

Active Ingredients

BetamethasoneFlorfenicolTerbinafine

Administration Routes

Auricular (Otic)UnknownTopicalOralIntraocularOphthalmicCutaneousOther

Species Affected

Dog 1,955
Cat 136
Unknown 115
Human 14
Other Cervids 1

Most Affected Breeds

Retriever - Labrador 296
Dog (unknown) 198
Unknown 132
Spaniel - Cocker American 110
Retriever - Golden 109
Domestic Shorthair 82
Shih Tzu 80
Shepherd Dog - German 71
Chihuahua 62
Terrier - Yorkshire 54

Most Reported Reactions

Lack of efficacy - NOS 1,128
Ear discharge 159
Loss of hearing 112
Vomiting 100
Lethargy (see also Central nervous system depression in 'Neurological') 91
Head shake - ear disorder 88
CULTURE/TITER DATA ABNORMAL 82
Deafness 80
Ear pain 75
Hearing decreased 75
Behavioural disorder NOS 73
Other abnormal test result NOS 71

Outcome Breakdown

Outcome Unknown
1,269 (60.3%)
Ongoing
484 (23.0%)
Recovered/Normal
261 (12.4%)
Recovered with Sequela
54 (2.6%)
Euthanized
21 (1.0%)
Died
17 (0.8%)

Data Summary

Metric Value
Total adverse event reports 2,221
Reports involving death 38
Case-fatality rate (reported events) 170.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Betamethasone + Florfenicol + Terbinafine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 2,221 adverse event reports referencing Betamethasone + Florfenicol + Terbinafine, including 38 reports in which the animal died — a 170.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Betamethasone, Florfenicol, Terbinafine. Reported administration routes include Auricular (Otic), Unknown, Topical, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Betamethasone + Florfenicol + Terbinafine reports are Dog (1,955 reports), Cat (136 reports), Unknown (115 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (296), Dog (unknown) (198), Unknown (132) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Betamethasone + Florfenicol + Terbinafine are Lack of efficacy - NOS (1,128), Ear discharge (159), Loss of hearing (112), Vomiting (100). Of the 2,106 reports with a coded outcome, Outcome Unknown is the leading category at 60.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Betamethasone + Florfenicol + Terbinafine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial